Novotech Releases Comprehensive Report on Oncolytic Virus Therapy
Explore the latest insights into global clinical trial trends, innovations, and strategies shaping the future of oncolytic virus therapy.
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122884484/en/
Oncolytic virus therapies utilize genetically modified or naturally occurring viruses to selectively target tumor cells and stimulate immune responses. This dual mechanism is creating new possibilities in oncology and other therapeutic areas.
Key Highlights:
- Global Trial Landscape: Asia-Pacific leads with 40% of OVT clinical trials, followed closely by North America and Europe, reflecting a global focus on advancing these therapies.
- Pipeline Insights: Solid tumors dominate OVT research, with trials targeting cancers such as melanoma, glioblastoma, and pancreatic cancer.
- Innovative Delivery Systems: Advances like nanoparticle systems and cell-based carriers address key challenges in targeting and delivery.
- Combination Therapies: Integration with immune checkpoint inhibitors, CAR-T therapies, and chemotherapy is enhancing the efficacy and scope of OVT.
- Regulatory Overview: Provides guidance on navigating complex global regulatory pathways, including insights into fast-tracking approvals.
This complimentary report offers biotech and pharmaceutical companies, data-driven analysis to navigate the complexities of clinical trials and regulatory frameworks in oncolytic virus therapy.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122884484/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pure Lithium Opens New Chicago Headquarters, Advancing Commercialization of Its Lithium Metal Battery22.10.2025 19:24:00 CEST | Press release
Pure Lithium Corp., a disruptive vertically integrated lithium metal battery technology company, officially opened its new headquarters in Chicago’s Fulton Market district with a ribbon cutting ceremony Tuesday attended by community and business leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022239586/en/ From left: Ken Hoffman, Pure Lithium Special Advisor; Dr. Yuan Gao, Member of Pure Lithium Scientific Advisory Board; Derek Willis, Vice President of Commercial Development at Oxy Low Carbon Ventures and Pure Lithium Board Director; Miss Illinois Nitsaniyah Fitch; Chicago Mayor Brandon Johnson; Pure Lithium Founder, Chairman & CEO Emilie Bodoin; Illinois State Senator Lakesia Collins; Former Massachusetts Governor & Pure Lithium Board Director William F. Weld; Lisa Clemmons-Stott, Senior Economic Advisor, Director’s Office, Illinois Department of Commerce and Economic Opportunity The opening marks a milestone in
Doha Debates Launches New Debate Season with Al Jazeera22.10.2025 19:07:00 CEST | Press release
The new season brings global voices together for truth-seeking discussions Qatar Foundation’s Doha Debates launched a new season of its flagship program, Doha Debates, on October 21, co-produced with Al Jazeera Digital. The upcoming season features high-profile guests, bold global themes and a renewed focus on open, truth-seeking dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022828303/en/ Qatar Foundation’s Doha Debates launches new debate season, bringing global voices together for truth-seeking discussions. (photo: AETOSWire) Airing weekly on Tuesdays through December 9, the eight-episode season explores three overarching themes—freedom, grand narratives and family. Each episode features leading thinkers and young changemakers engaging in timely conversations on the issues shaping humanity, ranging from meritocracy to social media; from love to architecture; from ancient traditions to the future of work. The
Picsart, Gen Z’s Preferred Digital Content Creation Platform, Takes LinkedIn Creators to Dracula’s Castle for “Why Your Marketing Sucks” Halloween Campaign22.10.2025 18:23:00 CEST | Press release
Picsart, the world’s leading digital creation platform, has announced the release of its new Halloween campaign and ebook, Why Your Marketing Sucks: a highly visual, tongue-in-cheek guide to the scariest mistakes marketers make and how to avoid them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022722043/en/ Why Your Marketing Sucks Ebook by Picsart The campaign, running from October 15 through October 31, combines horror-themed storytelling with practical marketing advice and expertise. Its centerpiece, the Why Your Marketing Sucks ebook, was co-created by Picsart and five top LinkedIn marketing influencers during an exclusive brand trip to Transylvania to visit Bran Castle — thought to be the home of Count Dracula himself. Picsart’s COO and Co-Founder, Mikayel Vardanyan, said “Gen Z represents more than 25% of today’s workforce. Picsart has been supporting this demographic for 15 years — more than half of our users ar
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 202522.10.2025 18:00:00 CEST | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held at the Hynes Convention Centerin Boston, MA, from October 22–26, 2025. Aurigene’s A-PROX platform integrates library screening, direct-to-biology chemistries, proprietary ternary complex assays, modelling algorithms, and structure-based design to accelerate the discovery and optimization of both protein degraders, molecular glues and proximity inducers. Through this integrated approach, Aurigene has advanced a strong pre-clinical portfolio of next-generation degraders, includinga SMARCA2-selective degrader, which recently received Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA); a pan-KRA
Visa Live Takes Flight with Benson Boone at the Rocket Garden22.10.2025 17:30:00 CEST | Press release
From le Louvre to the Launch Pad, Visa Live returns with another unforgettable music experience that puts fans at the center of the action. Prepare for lift-off this November as Visa presents another unforgettable cultural moment with Visa Live at the Rocket Gardenfeaturing global chart-topping sensation, Benson Boone on November 29. After the global success of Visa Live at le Louvre, the next chapter of the series lands at one of the world’s most iconic locations, the Rocket Garden at Kennedy Space Center Visitor Complex in Merritt Island, Florida. Headlined by Benson Boone, with a special guest to be announced, this event will be livestreamed on TikTok, inviting fans everywhere to join a night of music under the stars in a setting typically reserved for daylight exploration. “The Visa Live experience speaks to a fundamental truth in music: the space or environment in which the music is performed actually matters to both the artist and the audience,” said Frank Cooper III, Chief Marke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom